T-lymphocyte antigens

T-lymphocyte antigens refer to a broad and heterogeneous group of cell surface proteins expressed on T-cells that are fundamental to the adaptive immune response (Janeway et al., 2001). This category encompasses the T-cell receptor (TCR) complex, which identifies specific antigens, and co-receptors such as CD4 and CD8 that stabilize these interactions (StatPearls, 2023). It also includes critical regulatory molecules, such as costimulatory receptors (e.g., CD28) and inhibitory checkpoint receptors (e.g., CTLA-4 and PD-1), which act to either promote or dampen T-cell activation and exhaustion (Pardoll, 2012). These antigens play a central role in various diseases; for instance, the over-activation of T-cells can lead to autoimmune disorders, while their suppression is a hallmark of cancer immune evasion (NCBI MeSH, 2024). Consequently, these proteins are major targets for therapeutic intervention. Checkpoint inhibitors like ipilimumab and nivolumab target CTLA-4 and PD-1 respectively to treat malignancies, while other agents like muromonab-CD3 are used to prevent organ transplant rejection by targeting the CD3 complex (UniProt, 2024). Because the term T-lymphocyte antigens describes a functional class of proteins rather than a single molecular entity, the specific biological impact and safety profile of a drug depend entirely on which individual antigen is being modulated.

Other names

T-cell antigensT-cell surface markersCD antigensT-lymphocyte surface glycoproteins

Modulation of T-cell activity through checkpoint inhibition, costimulatory signal blockade, or direct T-cell depletion and redirection.